학술논문
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.
Document Type
article
Author
Kanapka, Lauren; Wadwa, R; Breton, Marc; Ruedy, Katrina; Ekhlaspour, Laya; Forlenza, Gregory; Cengiz, Eda; Schoelwer, Melissa; Jost, Emily; Carria, Lori; Emory, Emma; Hsu, Liana; Weinzimer, Stuart; DeBoer, Mark; Buckingham, Bruce; Oliveri, Mary; Kollman, Craig; Dokken, Betsy; Cherñavvsky, Daniel; Beck, Roy
Source
Diabetes reviews (Alexandria, Va.). 44(2)
Subject
Language
Abstract
OBJECTIVE: To further evaluate the safety and efficacy of the Control-IQ closed-loop control (CLC) system in children with type 1 diabetes. RESEARCH DESIGN AND METHODS: After a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children 6-13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks. RESULTS: In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55 ± 13% using SAP during the RCT to 65 ± 10% using CLC (P < 0.001), with 36% of the cohort achieving TIR >70% plus time